Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned a consensus rating of “Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $12.7692.

A number of equities analysts have issued reports on the company. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Pivotal Research set a $14.00 price objective on Taysha Gene Therapies in a research note on Tuesday, June 23rd. The Goldman Sachs Group raised their target price on Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Wednesday, June 24th.

Taysha Gene Therapies Stock Up 4.4%

Taysha Gene Therapies stock opened at $6.21 on Tuesday. Taysha Gene Therapies has a 52 week low of $2.71 and a 52 week high of $7.30. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -14.79 and a beta of 1.22. The company’s 50-day moving average price is $6.12 and its two-hundred day moving average price is $5.50. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts expect that Taysha Gene Therapies will post -0.51 EPS for the current fiscal year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the transaction, the insider owned 936,410 shares of the company’s stock, valued at $5,843,198.40. The trade was a 17.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Intech Investment Management LLC boosted its holdings in Taysha Gene Therapies by 3.6% during the fourth quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock worth $391,000 after buying an additional 2,443 shares in the last quarter. Chicago Partners Investment Group LLC increased its holdings in shares of Taysha Gene Therapies by 1.5% in the fourth quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after buying an additional 2,504 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Taysha Gene Therapies by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock valued at $73,000 after acquiring an additional 2,765 shares during the last quarter. Virtus Investment Advisers LLC lifted its position in shares of Taysha Gene Therapies by 7.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock valued at $253,000 after acquiring an additional 3,008 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Taysha Gene Therapies by 26.2% during the 1st quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock worth $72,000 after acquiring an additional 3,362 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.